Supporting treatment decisions for patients with Alzheimer's disease using explainable artificial intelligence

Norway Life Science 2026, January 12, 2026

Esten H. Leonardsen

Chief Scientific Officer, baba.vision

Post-doctoral research fellow,
Department of Psychology,
University of Oslo

baba vision

New treatment options for Alzheimer’s disease

New medications

New treatment options for Alzheimer's disease



Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*, *388*(1), 9-21.



Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & Kaul, S. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*, *330*(6), 512-527.

New treatment options for Alzheimer’s disease



New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer’s disease



New treatment options for Alzheimer's disease



Treatment eligibility

Explainable artificial intelligence

The future of Alzheimer’s treatment

Thank you for your attention!

esten@baba-vision.com



baba vision